Abnormal serum free light chain ratio predicts poor overall survival in mantle cell lymphoma

被引：14

作者：

Furtado, Michelle ^{[1
]}

Shah, Nimish

Levoguer, Alison ^{[2
]}

Harding, Stephen ^{[2
]}

Rule, Simon

机构：

[1] Derriford Hosp, Dept Haematol, Combined Labs, Plymouth PL6 8DH, Devon, England

[2] Binding Site Grp, Birmingham, W Midlands, England

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2013年 / 160卷 / 01期

关键词：

serum free light chains; mantle cell lymphoma; lenalidomide; biomarker; overall survival; MYELOMA;

D O I：

10.1111/bjh.12094

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Serum free light Chain (sFLC) ratios have been correlated with survival outcomes in Hodgkin and non-Hodgkin lymphoma subtypes. This study was undertaken to investigate the prognostic impact of abnormal sFLC ratios in mantle cell lymphoma (MCL). two patient cohorts were analysed for sFLC parameters: a preliminary retrospective cohort and a uniformly treated cohort of 20 relapsed/refractory MCL patients, enrolled in a phase II clinical trial of single agent lenalidomide treatment. 52% of patients had an abnormality of one or more sFLC parameter (71% of the first cohort and 40% of the second cohort). In cohort two, a high baseline SFLC ratio correlated with poorer overall survival (OS) compared to a low/normal ratio (median OS: 1.4 months vs. 19 months respectively; P = 0.001). For patients presenting with an elevated sFLC ratio at trial entry a rise of >35% in the sFLC ratio correlated with disease progression and a sFLC ratio of >2x normal at trial entry correlated with aggressive disease. These data are the first to show a clear clinical correlation between sFLC ratios and survival outcomes in a uniformly treated cohort of MCL patients. We suggest that these markers may be useful in managing patients with MCL in the future.

引用

页码：63 / 69

页数：7

共 26 条

[1] Guidelines for the diagnosis and management of multiple myeloma 2011 [J].

Bird, Jennifer M. ;

Owen, Roger G. ;

D'Sa, Shirley ;

Snowden, John A. ;

Pratt, Guy ;

Ashcroft, John ;

Yong, Kwee ;

Cook, Gordon ;

Feyler, Sylvia ;

Davies, Faith ;

Morgan, Gareth ;

Cavenagh, Jamie ;

Low, Eric ;

Behrens, Judith .

BRITISH JOURNAL OF HAEMATOLOGY, 2011, 154 (01) :32-75

[2] UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS) [J].

Bird, Jenny ;

Behrens, Judith ;

Westin, Jan ;

Turesson, Ingemar ;

Drayson, Mark ;

Beetham, Robert ;

D'Sa, Shirley ;

Soutar, Richard ;

Waage, Anders ;

Gulbrandsen, Nina ;

Gregersen, Henrik ;

Low, Eric .

BRITISH JOURNAL OF HAEMATOLOGY, 2009, 147 (01) :22-42

[3]

Bradwell AR, 2001, CLIN CHEM, V47, P673

[4] Immunoglobulin free light chains and solitary plasmacytoma of bone [J].

Dingli, David ;

Kyle, Robert A. ;

Rajkumar, S. Vincent ;

Nowakowski, Grzegorz S. ;

Larson, Dirk R. ;

Bida, John P. ;

Gertz, Morie A. ;

Therneau, Terry M. ;

Melton, L. Joseph, III ;

Dispenzieri, Angela ;

Katzmann, Jerry A. .

BLOOD, 2006, 108 (06) :1979-1983

[5] Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation [J].

Dispenzieri, A ;

Lacy, MQ ;

Katzmann, JA ;

Rajkumar, SV ;

Abraham, RS ;

Hayman, SR ;

Kumar, SK ;

Clark, R ;

Kyle, RA ;

Litzow, MR ;

Inwards, DJ ;

Ansell, SM ;

Micallef, IM ;

Porrata, LF ;

Elliott, MA ;

Johnston, PB ;

Greipp, PR ;

Witzig, TE ;

Zeldenrust, SR ;

Russell, SJ ;

Gastineau, D ;

Gertz, MA .

BLOOD, 2006, 107 (08) :3378-3383

[6] International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders [J].

Dispenzieri, A. ;

Kyle, R. ;

Merlini, G. ;

Miguel, J. S. ;

Ludwig, H. ;

Hajek, R. ;

Palumbo, A. ;

Jagannath, S. ;

Blade, J. ;

Lonial, S. ;

Dimopoulos, M. ;

Comenzo, R. ;

Einsele, H. ;

Barlogie, B. ;

Anderson, K. ;

Gertz, M. ;

Harousseau, J. L. ;

Attal, M. ;

Tosi, P. ;

Sonneveld, P. ;

Boccadoro, M. ;

Morgan, G. ;

Richardson, P. ;

Sezer, O. ;

Mateos, M. V. ;

Cavo, M. ;

Joshua, D. ;

Turesson, I. ;

Chen, W. ;

Shimizu, K. ;

Powles, R. ;

Rajkumar, S. V. ;

Durie, B. G. M. .

LEUKEMIA, 2009, 23 (02) :215-224

[7] Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma [J].

Dispenzieri, Angela ;

Kyle, Robert A. ;

Katzmann, Jerry A. ;

Therneau, Terry M. ;

Larson, Dirk ;

Benson, Joanne ;

Clark, Raynell J. ;

Melton, L. Joseph, III ;

Gertz, Morie A. ;

Kumar, Shaji K. ;

Fonseca, Rafael ;

Jelinek, Diane F. ;

Rajkumar, S. Vincent .

BLOOD, 2008, 111 (02) :785-789

[8] Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma [J].

Drayson, M ;

Tang, LX ;

Drew, R ;

Mead, GP ;

Carr-Smith, H ;

Bradwell, AR .

BLOOD, 2001, 97 (09) :2900-2902

[9] Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials [J].

Drayson, Mark ;

Begum, Gulnaz ;

Basu, Supratik ;

Makkuni, Sudhaker ;

Dunn, Janet ;

Barth, Nicola ;

Child, J. Anthony .

BLOOD, 2006, 108 (06) :2013-2019

[10]

Filippi R. D., 2008, HEMATOLOGY M REPORTS, V2, p18a

← 1 2 3 →